Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin
US-based Purdue Pharma, makers of painkiller OxyContin agreed to pay $600 million in fines and other payments to resolve the criminal charge of misbranding the product , one of the largest amounts ever paid by a drug company in such a case. Three of its current and former executives pleaded gu...When Your Breakfast is Considered a 'Drug'
...at include product/drug claims, marketers and their agents should consider the broad definition of "labeling" under the Act and the ramifications of a misbranding claim. If you would like to continue to receive periodic updates on regulatory developments from the FDA and State and Federal authorities, pl...US Drugmaker Slapped Huge Fine for Misleading Doctors Over Addictive Painkiller
...sales and also pleaded guilty to charges of playing down Oxycontins addictive and euphoric properties. Purdue pleaded guilty to a felony count of misbranding a drug with intent to defraud and mislead. Under the agreement, it will pay a $600 million settlement, including a criminal fine, restitution to ...Raids By US Marshals Uncovers Cache’ Of Unapproved Drug
...Nutraceuticals L.L.C distributed the capsules. Sources have indicated that the seized capsules, which are supposedly in violation of new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act, include, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support. I...Dietary supplements manufacturers gain new tool to help ensure quality products
...al origin and their dosage forms. USPNF is considered an official compendium under the Federal Food, Drug, and Cosmetic Act (FDCA), with the FDCA food misbranding provisions applying to any dietary supplement product represented as conforming to compendial specifications (and such products being deemed misbrande...